Investigating the effects of stopping antipsychotic medications during pregnancy
Relapse after Discontinuation of Antipsychotics during Pregnancy (R-DAP study)
This study is looking at how stopping antipsychotic medications during pregnancy affects women with bipolar disorder, to help understand the risks and provide better advice for moms-to-be about their treatment options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11015801 on NIH RePORTER |
What this research studies
This research examines the risks associated with discontinuing antipsychotic medications in women with bipolar disorder during pregnancy. It aims to understand how stopping these medications can lead to relapse, which poses significant health risks for both the mother and the child. The study will involve monitoring women who are pregnant or planning to become pregnant, assessing their mental health and medication use, and comparing outcomes for those who continue versus those who stop their medications. The goal is to provide clearer guidance on the safety and efficacy of antipsychotic treatments during this critical period.
Who could benefit from this research
Good fit: Ideal candidates for this research are pregnant women or those planning to become pregnant who have a diagnosis of bipolar disorder and are considering stopping their antipsychotic medications.
Not a fit: Patients who are not diagnosed with bipolar disorder or who are not pregnant or planning to become pregnant may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide vital insights that help prevent relapse in pregnant women with bipolar disorder, improving outcomes for both mothers and their children.
How similar studies have performed: Previous research has shown limited risks associated with discontinuing antidepressants in pregnant women, but this specific investigation into antipsychotic medications is novel and untested.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Bergink, Veerle — Icahn School of Medicine at Mount Sinai
- Study coordinator: Bergink, Veerle
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.